adenoviru
vector
vaccin
highli
effect
strategi
induc
cellular
immun
respons
particularli
effect
intracellular
pathogen
recombin
simian
adenoviru
vector
develop
circumv
limit
impos
use
human
adenovirus
due
widespread
seropreval
neutralis
antibodi
construct
replic
defici
simian
adenovirusvector
vaccin
express
gene
mycobacterium
avium
subspeci
paratuberculosi
ahpc
gsd
mpa
safeti
tcell
immunogen
result
first
clinic
use
vector
present
trial
conduct
use
threeplusthre
dose
escal
studi
design
demonstr
vaccin
safe
well
toler
immunogen
viral
vector
vaccin
known
effect
mechan
induc
cellular
respons
compar
subunit
vaccin
induc
protect
cell
respons
intracellular
pathogen
recombin
virus
excel
vehicl
vaccin
deliveri
viral
protein
act
potent
adjuv
directli
infect
antigenpres
cell
adenovirus
highli
attract
vector
human
vaccin
possess
stabl
genom
prevent
insert
foreign
gene
delet
infect
larg
number
cell
without
evid
insert
mutagenesi
human
adenoviru
vector
use
extens
clinic
trial
excel
safeti
profil
mainli
vector
human
immunodefici
viru
hiv
vaccin
howev
ubiqu
human
adenoviru
infect
gener
level
host
antivector
immun
may
limit
util
vector
preexist
immun
circumv
employ
vector
base
close
relat
simian
adenovirus
significantli
lower
seropreval
rate
human
popul
replicationdefici
adenoviru
vector
may
produc
remov
gene
viral
genom
essenti
viral
replic
suppli
gene
product
via
product
cell
line
gene
may
also
delet
increas
space
avail
within
viral
genom
addit
requir
antigen
target
downstream
mammalian
promot
direct
express
vaccin
insert
insid
transduc
cell
vaccin
mycobacterium
avium
subspeci
paratuberculosi
map
slow
grow
fastidi
gramposit
acidfast
nonchromogen
microorgan
known
caus
agent
chronic
granulomat
enter
rumin
john
diseas
zoonot
potenti
suggest
sinc
similar
two
chronic
inflammatori
bowel
diseas
first
describ
john
diseas
cattl
would
later
defin
crohn
diseas
cd
human
map
widespread
environ
result
shed
faec
infect
rumin
presenc
farm
anim
reservoir
larg
scale
environment
contamin
lead
inevit
human
popul
exposur
food
chain
also
contamin
soil
water
suppli
aerosol
crohn
diseas
debilit
chronic
inflammatori
bowel
condit
unknown
aetiolog
multifactori
pathogenesi
complex
interact
genet
environment
factor
map
infect
suggest
potenti
caus
agent
cd
establish
associ
map
infect
crohn
diseas
although
question
exact
role
remain
unansw
map
also
associ
hypothes
play
role
autoimmun
diseas
diabet
multipl
sclerosi
first
clinic
trial
recombin
chimpanze
adenoviru
vector
express
gene
map
describ
vaccin
antigen
consist
fusion
construct
ahpc
gsd
mpa
map
gene
present
map
strain
antigen
name
hav
describ
elsewher
safeti
cellular
immunogen
assess
healthi
adult
volunt
receiv
singl
dose
vaccin
firstinhuman
nonrandomis
openlabel
dose
escal
phase
trial
review
approv
within
uk
medicin
healthcar
product
regulatori
agenc
region
ethic
committe
regist
clinicaltrialsgov
identifi
male
femal
healthi
adult
volunt
age
year
recruit
enrol
group
figur
consort
diagram
centr
clinic
vaccinolog
tropic
medicin
churchil
hospit
oxford
uk
written
inform
consent
obtain
case
trial
perform
accord
princip
declar
helsinki
volunt
enrol
dose
escal
accord
threeplusthre
studi
design
previous
describ
vaccin
given
intramuscularli
deltoid
first
volunt
vaccin
viral
particl
vp
hav
volunt
vaccin
hour
elaps
follow
first
vaccin
sever
seriou
advers
reaction
occur
therefor
two
volunt
vaccin
vp
dose
follow
review
safeti
data
day
post
vaccin
profil
advers
reaction
found
accept
first
particip
next
increment
dose
group
enrol
vp
hav
dose
gradual
increas
vp
hav
follow
procedur
aim
provid
optim
dose
consid
toler
reactogen
immunogen
profil
three
particip
receiv
hav
vp
anoth
volunt
vaccin
vp
none
particip
present
either
sever
seriou
advers
reaction
particip
vaccin
vp
dose
given
favour
safeti
profil
top
dose
group
expand
maximum
volunt
gener
addit
safeti
immunogen
data
six
particip
previous
receiv
adenovir
vector
vaccin
month
enrol
part
clinic
trial
malaria
ebola
candid
vaccin
five
previous
given
chimpanze
adenoviru
serotyp
vector
vaccin
one
particip
chimpanze
adenoviru
serotyp
vector
vaccin
blood
sampl
taken
predefin
time
point
assess
haematolog
biochem
paramet
assess
immunogen
case
vaccin
administ
deltoid
muscl
observ
taken
hour
vaccin
volunt
follow
month
complet
electron
diari
regard
advers
event
week
follow
vaccin
primari
object
assess
safeti
reactogen
measur
occurr
solicit
local
reactogen
sign
symptom
day
follow
vaccin
b
occurr
solicit
system
reactogen
sign
symptom
day
follow
vaccin
c
occurr
unsolicit
advers
event
day
follow
vaccin
chang
baselin
safeti
laboratori
measur
e
occurr
seriou
advers
event
whole
studi
durat
secondari
object
assess
cellular
immunogen
hav
measur
enzymelink
immunospot
elispot
hav
vaccin
consist
replicationdefici
simian
adenoviru
vector
contain
fusion
construct
map
gene
present
map
strain
name
hav
ahpc
map
gsd
mpa
replicationdefect
delet
chimpanze
adenoviru
vector
produc
start
wildtyp
replicationcompet
isol
speci
adenoviru
e
also
known
pan
modif
region
vector
construct
bacteri
artifici
chromosom
bac
facilit
genet
manipul
genom
clone
improv
stabil
flexibl
gener
molecular
clone
genom
bac
gap
repair
vector
construct
contain
polymeras
chain
reaction
pcr
amplifi
region
homolog
left
right
flank
viral
genom
describ
elsewher
extra
homolog
flank
downstream
adenoviru
region
includ
enabl
delet
placement
uniqu
restrict
site
locu
concomit
genom
insert
bac
region
essenti
viral
replic
henc
abil
delet
stage
render
new
vector
immedi
replic
incompet
replic
incompet
clone
success
identifi
pcr
screen
transfect
complement
human
embryon
kidney
cell
confirm
abil
candid
clone
new
vector
gener
infecti
virion
galactokinas
galk
recombin
use
delet
nonessenti
adenoviru
region
increas
insert
capac
new
vector
approxim
protein
encod
region
adenovirus
interact
viral
replic
imperfect
interact
gene
product
gene
produc
cell
simian
gene
product
found
result
impair
viral
replic
cell
line
consequ
lower
viru
yield
construct
whole
nativ
region
replac
code
region
code
region
express
hav
insert
driven
human
cytomegaloviru
immedi
earli
promot
insert
recombin
antigen
locu
perform
use
gateway
site
specif
recombin
technolog
invitrogenthermo
fisher
waltham
massachusett
usa
hav
manufactur
clinic
good
manufactur
practic
cgmp
clinic
biomanufactur
facil
univers
oxford
oxford
uk
cell
line
vector
vaccin
purifi
steril
filter
gener
clinic
lot
concentr
vp
per
ml
respons
vaccin
hav
assess
elispot
assay
use
freshlyisol
peripher
blood
mononuclear
cell
pbmc
stimul
pool
peptid
span
hav
vaccin
construct
assay
perform
prior
vaccin
day
one
two
month
post
vaccin
day
methodolog
describ
previous
except
pbmc
assay
per
well
result
express
spot
form
unit
sfu
per
million
pbmc
calcul
subtract
mean
neg
control
respons
mean
peptid
pool
respons
sum
respons
eight
peptid
pool
pool
contain
mer
peptid
overlap
amino
acid
span
complet
vaccin
insert
peptid
pool
pool
contain
peptid
one
antigen
insert
elispot
plate
exclud
respons
sfumillion
pbmc
neg
control
medium
well
sfumillion
pbmc
posit
control
phytohemagglutininstaphylococc
enterotoxin
b
well
qualiti
control
qc
criteria
defin
prior
commenc
sampl
analysi
one
sampl
assay
middl
dose
group
remov
dataset
due
high
background
neg
control
well
safeti
end
point
describ
frequenc
percentag
alongsid
confid
interv
statist
analysi
immunogen
data
conduct
use
graphpad
prism
version
window
graphpad
softwar
inc
california
usa
median
interquartil
rang
given
paramet
comparison
time
point
baselin
perform
use
nonparametr
test
alpha
valu
consid
signific
nab
titer
vector
measur
use
secret
embryon
alkalin
phosphatasereport
seap
assay
previous
describ
measur
reciproc
serum
dilut
requir
reduc
vitro
express
vectorexpress
seap
hour
post
transduct
relat
adenoviru
vector
produc
wildtyp
vector
previous
employ
vector
influenza
tuberculosi
rift
valley
fever
viru
vaccin
candid
seapexpress
preincub
equal
volum
serial
dilut
heat
inactiv
c
minut
human
sera
dilut
hour
c
pool
sera
known
high
neutral
titr
greater
individu
sera
known
neutralis
titr
plu
known
unreact
sera
use
posit
neg
control
respect
follow
incub
serum
viru
dilut
use
transduc
griptit
macrophag
scaveng
receptor
msr
cell
invitrogen
carlsbad
ca
seed
plate
cellswel
cell
supernat
collect
hour
post
transduct
seap
concentr
quantifi
use
tropix
phosphalit
chemiluminesc
assay
kit
appli
biosystem
warrington
uk
luminesc
measur
use
varioskan
flash
luminomet
thermo
scientif
loughborough
uk
neutral
titer
express
reciproc
serum
dilut
requir
reduc
seap
express
hour
post
transduct
linear
interpol
adjac
valu
twelv
male
femal
healthi
adult
volunt
age
year
enrol
group
receiv
singl
dose
hav
consort
diagram
use
dose
escal
approach
describ
method
section
median
age
particip
year
rang
femal
volunt
vaccin
centr
clinic
vaccinolog
tropic
medicin
oxford
uk
march
june
particip
attend
seri
followup
visit
safeti
immunolog
purpos
month
post
vaccin
long
term
followup
seriou
advers
event
conduct
month
enrol
seriou
advers
reaction
follow
vaccin
hav
given
dose
neither
object
fever
sever
ae
consid
least
possibl
relat
vaccin
report
vast
major
ae
mild
natur
ci
selflimit
pain
inject
site
resolv
within
day
ae
resolv
within
h
prior
vaccin
respons
hav
antigen
low
geometr
mean
respons
ci
spotform
cell
sfc
per
million
pbmc
increas
geometr
mean
sfc
ci
day
take
averag
across
dose
group
figur
respons
highest
day
particip
immunis
vp
significantli
increas
vaccin
dose
group
p
kruskallw
test
dunn
multipl
comparison
test
compar
respons
respons
detect
antigen
day
geometr
mean
respons
rang
follow
sfc
sfc
sfc
per
million
pbmc
figur
antivector
neutralis
antibodi
analysi
perform
establish
whether
volunt
enrol
studi
preexist
nab
relat
vector
figur
volunt
neutral
titr
seap
assay
classifi
neg
titr
consid
low
accord
publish
clinic
studi
two
particip
test
higher
level
preexist
nab
titr
vector
vaccin
month
enrol
seven
particip
low
level
titr
previous
receiv
vector
vaccin
particip
seroneg
previous
receiv
vector
vaccin
nab
prior
vaccin
titr
follow
vaccin
hav
seroneg
particip
seroconvert
nab
titr
rang
day
titr
increas
significantli
vaccin
remain
significantli
baselin
friedman
test
dunn
multipl
comparison
test
p
day
p
day
effect
dose
nab
titr
assess
due
small
group
size
associ
preexist
nab
baselin
failur
reach
least
increas
tcell
respons
confirm
although
sampl
size
small
reach
definit
conclus
rel
risk
confid
interv
fisher
exact
test
p
see
figur
linear
regress
neutralis
titr
also
measur
anoth
replic
defici
adenovir
vector
preexist
titr
detect
particip
low
respons
increas
significantli
vaccin
either
friedman
test
dunn
multipl
comparison
test
p
adenoviru
vector
highli
effect
carrier
deliveri
foreign
antigen
host
cell
elicit
specif
antibodi
cell
respons
recombin
human
simian
adenoviru
vector
vaccin
extens
use
clinic
trial
infecti
diseas
cancer
vaccin
thousand
volunt
enrol
studi
investig
vaccin
hiv
malaria
tuberculosi
influenza
recent
ebola
cell
respons
known
main
protect
mechan
intracellular
pathogen
infect
vaccin
strategi
organ
tradit
focus
use
whole
live
attenu
inactiv
microorgan
mean
elicit
cellular
immun
respons
howev
use
replic
compet
live
attenu
vaccin
carri
risk
inadequ
attenu
potenti
lead
dissemin
diseas
particularli
immunocompromis
host
use
replic
defici
vector
therefor
avoid
risk
dissemin
diseas
whilst
maintain
advantag
nativ
antigen
present
elicit
cell
immun
abil
express
multipl
antigen
studi
first
clinic
use
novel
recombin
replic
defici
chimpanze
adenoviru
vaccin
vector
hav
vaccin
shown
safe
dose
vp
follow
dose
escal
approach
use
threeplusthre
studi
design
vaccin
well
toler
dose
test
accept
reactogen
highest
dose
group
seriou
advers
event
report
vast
major
symptom
mild
natur
report
solicit
unsolicit
ae
selflimit
complet
resolv
day
profil
advers
event
report
trial
similar
compar
close
relat
simian
adenoviru
express
sever
differ
antigen
vector
vaccin
vector
vaccin
better
toler
less
reactogen
vp
dose
predecessor
vector
vaccin
express
influenza
antigen
volunt
develop
object
fever
also
report
sever
local
system
ae
dose
tcell
respons
significantli
higher
baselin
post
vaccin
hav
volunt
enrol
intermedi
dose
group
vp
volunt
group
express
fold
higher
tcell
respons
whole
antigen
day
compar
baselin
assess
day
one
explan
modest
immunogen
observ
higher
dose
group
could
presenc
antivector
neutralis
antibodi
prior
vaccin
volunt
enrol
group
previous
receiv
adenoviru
vector
vaccin
encod
differ
antigen
year
enrol
howev
particip
receiv
highest
dose
higher
titr
vector
baselin
particip
group
low
titr
baselin
rang
develop
recombin
simian
adenoviru
deriv
rare
serotyp
driven
presenc
high
level
preexist
antibodi
human
adenovirus
vaccin
vector
candid
cross
reactiv
human
adenoviru
vector
aris
natur
infect
well
establish
howev
signific
prior
humor
cellular
immun
simian
adenoviru
vector
exampl
could
crossreact
describ
show
consider
variabl
seropreval
respons
vaccin
vaccin
induc
signific
increas
neutral
antibodi
titr
vector
howev
despit
wide
report
crossreact
human
adenovirus
induct
high
titr
neutralis
antibodi
induc
detect
increas
titr
relat
adenovir
vector
suggest
use
multipl
viral
vector
differ
candid
vaccin
advers
affect
crossreact
neutralis
antibodi
primeboost
regimen
shown
induc
maintain
high
level
cellular
immun
respons
therefor
second
dose
hav
might
need
order
achiev
sustain
cell
respons
past
day
post
vaccin
heterolog
primeboost
vaccin
schedul
antigen
given
differ
viral
vector
eg
adenoviru
prime
poxviru
boost
previous
shown
effect
homolog
primeboost
strategi
new
studi
assess
safeti
immunogen
simian
adenoviru
prime
modifi
vaccinia
ankara
vector
boost
mva
encod
ahpc
gsd
mpa
antigen
could
boost
tcell
respons
seen
hav
prime
conclus
novel
replic
defici
chimpanze
adenoviru
vector
encod
antigen
mycobacterium
avium
paratuberculosi
safe
well
toler
modestli
immunogen
healthi
adult
volunt
